Evoke Pharma (NASDAQ:EVOK) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Evoke Pharma (NASDAQ:EVOK) posted its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.02, Fidelity Earnings reports.

NASDAQ:EVOK traded up $0.03 during trading hours on Friday, reaching $0.90. The company’s stock had a trading volume of 33,600 shares, compared to its average volume of 554,915. The company has a market capitalization of $20.70 million, a P/E ratio of -1.96 and a beta of 1.53. Evoke Pharma has a 12 month low of $0.50 and a 12 month high of $3.26. The stock has a 50 day moving average price of $0.86 and a two-hundred day moving average price of $0.81.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Several research firms have recently weighed in on EVOK. Zacks Investment Research downgraded shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. HC Wainwright reaffirmed a “hold” rating on shares of Evoke Pharma in a research note on Friday, August 9th. Finally, ValuEngine raised shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Featured Story: How to Invest in a Bull Market

Earnings History for Evoke Pharma (NASDAQ:EVOK)

Leave a Reply

Your email address will not be published. Required fields are marked *